Additional file 1: Figure S1. of Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
Maud Marques
Marie-Claude Beauchamp
Hubert Fleury
Ido Laskov
Sun Qiang
Manuela Pelmus
Diane Provencher
Anne-Marie Mes-Masson
Walter Gotlieb
Michael Witcher
10.6084/m9.figshare.c.3615500_D1.v1
https://springernature.figshare.com/articles/figure/Additional_file_1_Figure_S1_of_Chemotherapy_reduces_PARP1_in_cancers_of_the_ovary_implications_for_future_clinical_trials_involving_PARP_inhibitors/4376582
PARP1 antibody validation. (A) Western blot of PARP1 and actin were performed on OVCAR8 cells infected with shRNA control or directed against PARP1. (B) The same cells used in (A) were paraffin-embedded and IHC staining against PARP1 was performed using the same antibody as in (A). The antibody shows high specificity and sensitivity for PARP1 protein in both techniques. (TIFF 1130Â kb)
2015-09-09 05:00:00
Chemotherapy
PARP inhibitors
PARP1
ovarian cancer